Spots Global Cancer Trial Database for cediranib
Every month we try and update this database with for cediranib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | NCT02484404 | Colorectal Neop... Breast Neoplasm... | Olaparib Cediranib Durvalumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX | NCT00384176 | Colorectal Canc... | Cediranib Bevacizumab 5-fluorouracil ... Leucovorin (in ... Oxaliplatin (in... | 18 Years - 130 Years | AstraZeneca | |
| AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | NCT01065662 | Endometrial Can... Ovarian Cancer Cervical Cancer Fallopian Tube ... Peritoneal Canc... | temsirolimus cediranib | 18 Years - | Dana-Farber Cancer Institute | |
| A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS) | NCT01337401 | Alveolar Soft-p... | Cediranib Placebo | 16 Years - | Institute of Cancer Research, United Kingdom | |
| Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | NCT02893917 | Advanced Prosta... Castration-Resi... Metastatic Pros... Metastatic Pros... Prostate Adenoc... Stage IV Prosta... | Cediranib Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer | NCT02855697 | Ovarian Cancer | Olaparib Cediranib Platinum-based ... | 18 Years - | The Christie NHS Foundation Trust | |
| Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer | NCT00399035 | Metastatic Colo... | Cediranib FOLFOX (5-fluor... XELOX (Capecita... Cediranib Place... | 18 Years - 130 Years | AstraZeneca | |
| Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients | NCT00960349 | Gastric Cancer | Cediranib Cisplatin S-1 Cisplatin Capecitabine | 20 Years - | AstraZeneca | |
| A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS) | NCT01337401 | Alveolar Soft-p... | Cediranib Placebo | 16 Years - | Institute of Cancer Research, United Kingdom | |
| Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib | NCT03314740 | Ovarian Neoplas... | Paclitaxel Cediranib Olaparib | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients | NCT00621361 | Lung Cancer | AZD2171 Etoposide Cisplatin | 18 Years - | AstraZeneca | |
| Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors | NCT03851614 | Mismatch Repair... Pancreatic Aden... Leiomyosarcoma | Durvalumab Olaparib Cediranib | 18 Years - | University Health Network, Toronto | |
| WIRE - Novel Treatments in Renal Cell Cancer | NCT03741426 | Renal Cell Canc... | Olaparib Cediranib Durvalumab | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer | NCT00399035 | Metastatic Colo... | Cediranib FOLFOX (5-fluor... XELOX (Capecita... Cediranib Place... | 18 Years - 130 Years | AstraZeneca | |
| Sunitinib or Cediranib for Alveolar Soft Part Sarcoma | NCT01391962 | Sarcoma, Alveol... | Cediranib Sunitinib | 16 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | NCT01208051 | Refractory Diff... Refractory Thyr... Refractory Thyr... Refractory Thyr... Unresectable Th... | Cediranib Cediranib Malea... Laboratory Biom... Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer | NCT02681237 | Ovarian Cancer | Cediranib Olaparib | 18 Years - | University Health Network, Toronto | |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | NCT02502266 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Cediranib Cediranib Malea... Computed Tomogr... Magnetic Resona... Olaparib Paclitaxel Pegylated Lipos... Questionnaire A... Topotecan Topotecan Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients | NCT00960349 | Gastric Cancer | Cediranib Cisplatin S-1 Cisplatin Capecitabine | 20 Years - | AstraZeneca | |
| DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study) | NCT00748891 | Cancer | Recentin (Cedir... | 18 Years - | AstraZeneca | |
| Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | NCT01208051 | Refractory Diff... Refractory Thyr... Refractory Thyr... Refractory Thyr... Unresectable Th... | Cediranib Cediranib Malea... Laboratory Biom... Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib or Cediranib for Alveolar Soft Part Sarcoma | NCT01391962 | Sarcoma, Alveol... | Cediranib Sunitinib | 16 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma | NCT00777153 | Recurrent Gliob... | Cediranib Cediranib Lomustine Chemo... Placebo Cediran... | 18 Years - 100 Years | AstraZeneca | |
| Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial | NCT01160926 | Rectal Cancer | AZD6244 Cediranib (AZD2... | 18 Years - | The Christie NHS Foundation Trust | |
| Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour | NCT00503204 | Recurrent Gliob... Brain Tumor | Cediranib Lomustine | 18 Years - | AstraZeneca | |
| Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™) | NCT00306891 | Cancer | Cediranib Cediranib 30 - ... | 18 Years - | AstraZeneca | |
| A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS) | NCT01337401 | Alveolar Soft-p... | Cediranib Placebo | 16 Years - | Institute of Cancer Research, United Kingdom | |
| An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer | NCT00532194 | Ovarian Cancer | cediranib | 18 Years - | Medical Research Council | |
| Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | NCT02974621 | Recurrent Gliob... | Bevacizumab Cediranib Cediranib Malea... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour | NCT00503204 | Recurrent Gliob... Brain Tumor | Cediranib Lomustine | 18 Years - | AstraZeneca | |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | NCT03660826 | Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? | NCT03570437 | Carcinosarcoma Endometrial Neo... | Paclitaxel Cediranib Olaparib | 16 Years - | University of Manchester | |
| Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers | NCT00939848 | Biliary Tract N... | gemcitabine cisplatin Placebo cisplatin cediranib gemcitabine | 18 Years - | University College, London | |
| Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer | NCT02899728 | Extensive Stage... | Carboplatin Cediranib Cediranib Malea... Cisplatin Etoposide Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers | NCT00939848 | Biliary Tract N... | gemcitabine cisplatin Placebo cisplatin cediranib gemcitabine | 18 Years - | University College, London | |
| A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS) | NCT01337401 | Alveolar Soft-p... | Cediranib Placebo | 16 Years - | Institute of Cancer Research, United Kingdom | |
| Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors | NCT03851614 | Mismatch Repair... Pancreatic Aden... Leiomyosarcoma | Durvalumab Olaparib Cediranib | 18 Years - | University Health Network, Toronto | |
| Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients | NCT00621361 | Lung Cancer | AZD2171 Etoposide Cisplatin | 18 Years - | AstraZeneca | |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | NCT03660826 | Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | NCT02484404 | Colorectal Neop... Breast Neoplasm... | Olaparib Cediranib Durvalumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours | NCT00750841 | Solid Tumors | cediranib | 18 Years - 130 Years | AstraZeneca | |
| Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib | NCT03314740 | Ovarian Neoplas... | Paclitaxel Cediranib Olaparib | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | NCT01065662 | Endometrial Can... Ovarian Cancer Cervical Cancer Fallopian Tube ... Peritoneal Canc... | temsirolimus cediranib | 18 Years - | Dana-Farber Cancer Institute | |
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | NCT02484404 | Colorectal Neop... Breast Neoplasm... | Olaparib Cediranib Durvalumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies | NCT01364051 | Metastatic Mela... Refractory Mali... Stage IV Cutane... Unresectable Ma... | Cediranib Cediranib Malea... Laboratory Biom... Pharmacological... Selumetinib Selumetinib Sul... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib | NCT02340611 | Ovarian Cancer | Olaparib Cediranib | 18 Years - | University Health Network, Toronto |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
